Further options for TKI-refractory ALK+ NSCLC patients currently include platinum-based doublets, especially with pemetrexed, and monochemotherapy alone or in combination of antiangiogenics (docetaxel in combination with nintedanib or ramucirumab) [113,114,115]. Here, ALK is linked to non-small cell lung carcinoma.